跳至主要内容
临床试验/NL-OMON55737
NL-OMON55737尚未招募2 期

A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the treatment of partial deep dermal and full thickness burns in children in comparison to autologous split-thickness skin grafts (STSG) - TBRU-dS-BC-PIIb

CUTISS AG0 个研究点目标入组 4 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
CUTISS AG
入组人数
4

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 11(—)

入选标准

  • Age: <12 years of age
  • Deep partial thickness and/or full-thickness burns requiring surgical
  • wound coverage
  • Expected that >=90 cm2 of wound (not counting the head and neck area
  • for study patients in The Netherlands) will remain open at 4 weeks post
  • burn despite proceeding with treatment in accordance with the standard
  • of care. >20% TBSA burns can be taken as guideline, but TBSA is not an
  • inclusion criterion.
  • Signed informed consent from the patient or the parents/legally authorized
  • representative.

排除标准

  • Patients tested positive for HBV, HCV, syphilis or HIV
  • Patients with known underlying or concomitant medical conditions that may
  • interfere with normal wound healing (e.g. systemic skin and connective tissue
  • diseases, any kind of congenital defect of metabolism including
  • insulin-dependent diabetes mellitus, Cushing syndrome or disease, scurvy,
  • chronic hypothyroidism, congenital or acquired immunosuppressive condition,
  • chronic renal failure, or chronic hepatic dysfunction (Child-Pugh class B or
  • C), severe malnutrition, or other concomitant illness which, in the opinion of
  • the Investigator, has the potential to significantly delay wound healing)
  • Severe drug and alcohol abuse
  • Pre-existing coagulation disorders as defined by INR outside its normal
  • value, PTT >ULN and fibrinogen / or at the Investigator*s discretion
  • Patients with known allergies to amphotericin B, gentamicin, penicillin or
  • streptomycin or bovine collagen
  • Previous enrolment of the patient into the current phase II study
  • Participation of the patient in another study with conflicting endpoints
  • within 30 days preceding and during the present study
  • Patients or parents/legal guardian expected not to comply with the study
  • protocol (including patients with severe cognitive dysfunction/impairment and
  • severe psychiatric disorders)
  • Pregnant or breast feeding females
  • Suspicion of non-accidental injury
  • Wounds in the head and neck area as study target area (only applicable
  • for study patients in The Netherlands)
  • Enrolment of the Investigator, his/her family members, employees and other
  • dependent persons

研究者

发起方
CUTISS AG

相似试验

进行中(未招募)
1 期
A study performed in more hospitals, to assess the safety and efficacy of a skin model that is engineered in the lab with cells of the patient (EHSG-KF) to use in treatment of partial deep dermal and full thickness burns in children and compare this to the treatment with the own skin system called STSG.Children with partial deep dermal and full thickness burns
EUCTR2017-002461-21-NLCUTISS AG12
招募中
2 期
A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the treatment of partial deep dermal and full thickness burns in adults and adolescents in comparison to autologous split-thickness skin grafts (STSG)ernstige brandwondendermal burnsskin damage due to heat
NL-OMON55581CUTISS AG4
进行中(未招募)
1 期
A study to check if the use of a skin model engeneered in the laboratory by using your own skin cells (EHSG-KF), is safe and effective to treat partial deep dermal and full thickness burns in adults in comparison to the standard treatment used in current medicine (STSG).
EUCTR2017-002460-41-ITniversity of Zurich, Tissue Biology Research Unit12
进行中(未招募)
1 期
A study to check if the use of a skin model engeneered in the laboratory by using your own skin cells (EHSG-KF), is safe and effective to treat partial deep dermal and full thickness burns in adults and adolescents in comparison to the standard treatment used in current medicine (STSG).Adults and adolescents with partial deep dermal and full thickness burns
EUCTR2017-002460-41-NLCUTISS AG12
进行中(未招募)
1 期
A study to check if the use of a skin model engeneered in the laboratory byusing your own skin cells (EHSG-KF), is safe and effective to treat partialdeep dermal and full thickness burns in children in comparison to thestandard treatment used in current medicine (STSG).
EUCTR2017-002461-21-ITniversity of Zurich, Tissue Biology Research Unit12